Agricultural biotech firm Evogene announced this week that its second quarter revenues rose to $129,000 from $10,500 in the second quarter last year.
The Israeli firm posted a net loss of $738,000, or $.05 per share, for the three months ended June 30, compared with a net loss of $836,000, or $.06 per share, for the comparable period a year ago.
The firm, which spun out of Compugen in 2002, recently inked collaborations with Bayer CropScience, alternative energy firm Ormat, and banana producer Rahan Meristem.
Evogene said it had $9.9 million in cash, cash equivalents, cash deposits, and short-term marketable securities as of the end of the quarter. Its cash holdings reflect funds from its initial public offering, which was completed on the Tel Aviv Stock Exchange in June.